Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Coulter

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Drug Safety|June 20, 2002
Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approachDavid M Coulter
The Journal of Pediatrics|March 12, 2011
Hyperglycemia in very low birth weight infantsDavid M Coulter
Journal of Perinatology : Official Journal of the California Perinatal Association|March 27, 2004
Successful treatment with octreotide of spontaneous chylothorax in a premature infantDavid M Coulter
The New England Journal of Medicine|February 10, 2009
Clostridium difficileDavid M Coulter
The New England Journal of Medicine|September 1, 2006
Caffeine for apnea of prematurityDavid M Coulter
Expert Opinion on Drug Safety|October 27, 2004
Disturbance of vision by COX-2 inhibitorsDavid M Coulter, David W J Clark
Pharmacoepidemiology and Drug Safety|August 6, 2003
Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena)Lifeng Zhou, Mira Harrison-Woolrych, David M Coulter
Drug Safety|November 26, 2008
Randomized controlled trials and assessment of drug safetyDavid W J Clark, David M Coulter, Frank M C Besag
Drug Safety|December 14, 2004
Linking pharmacovigilance with pharmacogeneticsDavid W J Clark, Emma Donnelly, David M Coulter, et al.
Headache|September 27, 2003
Activation of pain by sumatriptanDavid M Coulter, J L M Passier, David W J Clark, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Drug Safety|June 20, 2002
Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approachDavid M Coulter
The Journal of Pediatrics|March 12, 2011
Hyperglycemia in very low birth weight infantsDavid M Coulter
Journal of Perinatology : Official Journal of the California Perinatal Association|March 27, 2004
Successful treatment with octreotide of spontaneous chylothorax in a premature infantDavid M Coulter
The New England Journal of Medicine|February 10, 2009
Clostridium difficileDavid M Coulter
The New England Journal of Medicine|September 1, 2006
Caffeine for apnea of prematurityDavid M Coulter
Expert Opinion on Drug Safety|October 27, 2004
Disturbance of vision by COX-2 inhibitorsDavid M Coulter, David W J Clark
Pharmacoepidemiology and Drug Safety|August 6, 2003
Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena)Lifeng Zhou, Mira Harrison-Woolrych, David M Coulter
Drug Safety|November 26, 2008
Randomized controlled trials and assessment of drug safetyDavid W J Clark, David M Coulter, Frank M C Besag
Drug Safety|December 14, 2004
Linking pharmacovigilance with pharmacogeneticsDavid W J Clark, Emma Donnelly, David M Coulter, et al.
Headache|September 27, 2003
Activation of pain by sumatriptanDavid M Coulter, J L M Passier, David W J Clark, et al.
Pageof 2